PR-924 is primarily used in the field of medical research, particularly in the study of cancer and immune system regulation. It functions as a selective inhibitor of the immunoproteasome, which plays a crucial role in antigen presentation and immune response. By targeting this pathway, PR-924 helps researchers understand the mechanisms of diseases like multiple myeloma and other cancers that exploit the immunoproteasome for survival and proliferation. Its application in preclinical studies has provided insights into potential therapeutic strategies, making it a valuable tool in the development of treatments aimed at modulating immune responses and combating malignancies.